Stay updated with breaking news from Mark Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a single cell genomics-based therapeutics company, today announced the completion of a $58 million Series...
E-Mail The Mark Foundation for Cancer Research announces a $1 million grant to The Jackson Laboratory (JAX) to study the harmful side effects that sometimes occur in cancer patients treated with immunotherapy. The research will involve mice engineered with humanized immune systems to find specific gene variants that could explain why so many patients - as many as 10 percent - develop Type 1 diabetes while undergoing immunotherapy to treat cancer. The grant will also study and determine how to predict which patients may experience myocarditis, a rare but potentially deadly inflammation of th...
E-Mail IMAGE: The AstroPath platform allows for the assessment of the level of expression of a given marker on individual cells, while maintaining information on their spatial location. Shown here is... view more Credit: Seyoun Park, Ph.D. Pairing sky-mapping algorithms with advanced immunofluorescence imaging of cancer biopsies, researchers at The Mark Foundation Center for Advanced Genomics and Imaging at Johns Hopkins University and the Bloomberg~Kimmel Institute for Cancer Immunotherapy developed a robust platform to guide immunotherapy by predicting which cancers will respon...
Published: May 18, 2021 By Alex Keown Three companies on three separate continents raised more than $250 million to advance their scientific visions of supporting and developing new therapies for life-threatening diseases. Hummingbird Bioscience Raises $125 Million Singapore-based raised $125 million in an oversubscribed Series C financing round. The funds will be used to support the development of the company’s two lead programs and advance its early-stage clinical research. Hummingbird’s two lead assets are HMBD-001, a best-in-class HER3 antibody for NRG1-fusion and HER3-...
Evotec AG: Evotec SE Reports Results for The First Quarter 2021 and Provides Corporate Update GOOD PROGRESS WITHIN PRODUCT DEVELOPMENT PARTNERSHIPS AND CO-OWNED PORTFOLIO CONTINUED POSITIVE FINANCIAL PERFORMANCE; NO MATERIAL IMPACT THROUGH COVID-19 PANDEMIC HAMBURG, GERMANY / ACCESSWIRE / May 11, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the financial results and corporate updates for the first quarter 2021. HIGHLIGHTS RECORD LIKE-FOR-LIKE GROWTH OF BASE BUSINESS, STRONG BALANCE SHEET SUPPORTS ACCELERATING GROWTH Group revenues from cont...